Top 10 Oncology Capital Raises in the U.S. – December 16th-31st, 2024
Several interesting transactions closed in the Oncology sector over the past two weeks. If you would like more info on these deals or would like to discuss the capital raising market for your company, please contact me.
PIPE
-
- Lipella Pharmaceuticals, a clinical-stage biotechnology company, received $1.72 million of development capital from Spartan Capital Securities through a private placement.
- Psyence Biomed, a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing, received approximately $2 million of development capital through a private placement.
- TScan Therapeutics, a biopharmaceutical company focused on the development of T-cell receptor engineered T cell therapies for the treatment of patients with cancer, received $30 million of development capital from Lynx1 Capital Management.
Merger/Acquisition and Corporate
-
- Nova Pharmaceuticals, operator of a clinical-stage biotechnology company intended for metaplastic breast cancer patients, was acquired by Galera Therapeutics.
- Sherlock Biosciences, developer of a diagnostic platform designed to control disease in low-resource settings, was acquired by Orasure Technologies.
Later Stage VC
-
- Gregor Diagnostics, operator of a molecular diagnostics company intended to develop a revolutionary new screening test for prostate cancer, raised $7.43 million of venture funding in the form of convertible debt.
- Indapta Therapeutics, operator of a biotechnology company focused on developing a natural killer cell therapy with potent activity to treat cancer, raised $22.5 million of venture funding from Leaps by Bayer, Vertex Ventures HC and Pontifax Venture Capital.
- Linnaeus Therapeutics, developer of molecular therapeutics designed to treat cancer and skin pigmentation disorders, raised $6.86 million of Series B venture funding from Kairos Ventures and Penn Medicine Co-Investment Program.
Grant
-
- Marker Therapeutics, a clinical-stage immuno-oncology company, received $9.5 million of grant funding from Cancer Prevention and Research Institute of Texas.
- TigaTx, developer of a proprietary platform technology designed to activate the body’s neutrophils to fight cancer, received an estimated $35.5 million of grant funding from National Cancer Institute and ARPA-H.
#castleplacement #capitalraising #privateequity #venturecapital #investment #Oncology
Gary Levy
Managing Director
Over 30 years in financial services, including senior roles at Citi, Ivy Asset Management (an Affiliate of BNY) and TIAA. Founder and President of Biltmore Savings Consultants, a provider of B2B technology solutions to improve operations. Author of published book "21 Ways to Improve Your Business Operations." MBA - Strategic Business Management from Hofstra University’s Frank G. Zarb School of Business. BS (with a concentration in Business, Management and Economics) from SUNY Empire State College. Series 7, 63 and 79 licenses.
- Email: glevy@castleplacement.com
- (C) (516) 457-0104
 Gary LevyManaging Director |
Please contact me if you have any questions or would like to discuss your capital raise:
Email: glevy@castleplacement.com
(C) (516) 457-0104
Send us a message:
Sources: Information on this page was derived from a variety of sources including Bloomberg, Company Websites, Crunchbase, PitchBook and other news outlets. Castle Placement™ does not warrant or guarantee this information, nor makes any representations as to the accuracy of the information. For more Risks, see CPGO Risks and Disclaimers.
